Mesut Ã**¢**tÄon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5448282/publications.pdf

Version: 2024-02-01

68	897	16	27
papers	citations	h-index	g-index
70	70	70	1386
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Level of clinical evidence of herbal complementary therapies in psychiatric disorders. Journal of Theoretical Social Psychology, 2019, 29, 239-243.	1.9	5
2	Cannabis-associated psychotic symptoms and neurocognitive effects at high risk psychosis patients. Journal of Theoretical Social Psychology, 2018, 28, 1-3.	1.9	0
3	Triple reuptake inhibitors (TRIs): do they promise us a rose garden?. Journal of Theoretical Social Psychology, 2018, 28, 119-122.	1.9	5
4	Psychiatric pharmacogenomics in the age of neuroscience: promises and challenges. Journal of Theoretical Social Psychology, 2018, 28, 231-235.	1.9	5
5	Serious dermatological adverse effects of vortioxetine: two cases. Journal of Theoretical Social Psychology, 2018, 28, 355-357.	1.9	6
6	The Research Domain Criteria framework: transitioning from dimensional systems to integrating neuroscience and psychopathology. Journal of Theoretical Social Psychology, 2017, 27, 1-5.	1.9	4
7	Adverse drug reactions and causality: the Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Journal of Theoretical Social Psychology, 2017, 27, 205-206.	1.9	20
8	Brexanolone: an allosteric modulator of GABA-A receptors in the rapid treatment of postpartum depression. Journal of Theoretical Social Psychology, 2017, 27, 326-328.	1.9	5
9	Ketamine and electroconvulsive therapy pairing in depression and mood disorders. Journal of Theoretical Social Psychology, 2017, 27, 103-105.	1.9	1
10	An Update on Borderline Personality Disorder. Journal of Mood Disorders, 2017, , 1.	0.1	0
11	Over the Counter Purchase and Off-Label Use of Modafinil. Journal of Microbiology and Biotechnology, 2017, , 1.	2.1	0
12	Psychobiotics: The Potential Therapeutic Promise of Microbes in Psychiatry. Journal of Microbiology and Biotechnology, 2016, 26, 93-102.	2.1	5
13	The Neuroinflammation Perspective of Depression: Reuniting the Outstanding Mechanisms of the Pathophysiology. Journal of Microbiology and Biotechnology, 2016, 26, 196-206.	2.1	15
14	Fractional Anisotropic Changes of Corpus Callosum Associated with Antipsychotic Treatment in First-Episode Antipsychotic Drug-Naive Patients with Schizophrenia. Journal of Microbiology and Biotechnology, 2016, 26, 332-341.	2.1	1
15	\hat{l}^2 -adrenergic Receptor Blocker Use for Traumatic Memory Reconsolidation in Posttraumatic Stress Disorder. Journal of Microbiology and Biotechnology, 2016, 26, 215-222.	2.1	2
16	Risk Evaluation and Mitigation Strategy for Clozapine. Journal of Microbiology and Biotechnology, 2016, 26, 1-6.	2.1	4
17	Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide. Journal of Microbiology and Biotechnology, 2016, 26, 329-331.	2.1	3
18	Neuroinflammation in Schizophrenia: A Critical Review and The Future. Journal of Microbiology and Biotechnology, 2016, 26, 429-437.	2.1	23

#	Article	lF	CITATIONS
19	Childhood traumas in patients with bipolar disorder: association with alexithymia and dissociative experiences. Anadolu Psikiyatri Dergisi, 2016, 17, 188.	0.3	11
20	The microbiota and gut-brain axis. Journal of Mood Disorders, 2016, 6, 172.	0.1	1
21	An updated clozapine treatment guide against clozaphobic attitudes. Journal of Mood Disorders, 2016, 6, 242.	0.1	4
22	Involvement of Neuroactive Steroids in Pain, Depression and Anxiety. Modern Problems of Pharmacopsychiatry, 2015, 30, 94-102.	2.5	11
23	The Reliability and Validity of the Turkish Version of Psychopathy Checklist-Revised (Turkish PCL-R). Journal of Microbiology and Biotechnology, 2015, 25, 118-124.	2.1	6
24	A Futuristic Approach to Psychiatric Diagnosis. Journal of Microbiology and Biotechnology, 2015, 25, 321-325.	2.1	0
25	Over-the-Counter Purchase and Off-Label Use of Modafinil. Journal of Microbiology and Biotechnology, 2015, 25, 312-313.	2.1	0
26	Treatment of Schizophrenia: Past, Present and Future. Journal of Microbiology and Biotechnology, 2015, 25, 95-99.	2.1	1
27	Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia. Journal of Microbiology and Biotechnology, 2015, 25, 27-37.	2.1	5
28	Number Needed to Treat: an Important Measure for the Correct Assessment of Clinical Significance. Journal of Microbiology and Biotechnology, 2015, 25, 1-3.	2.1	1
29	Sights for Sore Eyes and Disappointments in Psychopharmacology. Journal of Microbiology and Biotechnology, 2014, 24, 111-114.	2.1	3
30	A Serious Risk: Excessive and Inappropriate Antipsychotic Prescribing. Journal of Microbiology and Biotechnology, 2014, 24, 1-4.	2.1	3
31	Clozaphobia: Fear of Prescribers of Clozapine for Treatment of Schizophrenia. Journal of Microbiology and Biotechnology, 2014, 24, 295-301.	2.1	21
32	Determination of aerobic biodegradation kinetics of olive oil mill wastewater. International Biodeterioration and Biodegradation, 2013, 85, 237-242.	3.9	18
33	Asenapine: A Novel Hope in the Treatment of Schizophrenia and Manic and Mixed Episodes of Bipolar I Disorder. Journal of Microbiology and Biotechnology, 2013, 23, 99-106.	2.1	0
34	Metacognitive Functions in Obsessive Compulsive Disorder in a Turkish Clinical Population: The Relationship Between Symptom Types and Metacognition Subdimensions. Journal of Microbiology and Biotechnology, 2013, 23, 65-71.	2.1	4
35	A report by Turkish Association for Psychopharmacology on the Psychotropic Drug Usage in Turkey and Medical, Ethical and Economical Consequences of Current Applications. Journal of Microbiology and Biotechnology, 2013, 23, 390-402.	2.1	3
36	Unmet needs in psychiatry and emerging novel pharmacological agents. Journal of Microbiology and Biotechnology, 2013, 23, 199-204.	2.1	1

#	Article	IF	CITATIONS
37	Past, Present and Future Psychiatric Trends in USA: Lessons for All. Journal of Microbiology and Biotechnology, 2012, 22, 205-209.	2.1	O
38	Nanotechnology Applications in Neuroscience: Advances, Opportunities and Challenges. Journal of Microbiology and Biotechnology, 2012, 22, 115-120.	2.1	6
39	Today's Psychopharmacological Treatments: Results, Problems, New Perspectives. Journal of Microbiology and Biotechnology, 2012, 22, 198-204.	2.1	3
40	Temperament traits and psychopathy in a group of patients with antisocial personality disorder. Comprehensive Psychiatry, 2011, 52, 607-612.	3.1	24
41	Synaptosomal- Associated Protein 25 Gene Polymorphisms and Antisocial Personality Disorder: Association with Temperament and Psychopathy. Canadian Journal of Psychiatry, 2011, 56, 341-347.	1.9	16
42	Clinical Characteristics of Self-Mutilating Behavior in Turkish Male Subjects With Antisocial Personality Disorder: Relationship To Psychopathy. International Journal of Social Psychiatry, 2011, 57, 237-247.	3.1	4
43	CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. Journal of Microbiology and Biotechnology, 2011, 21, 93-99.	2.1	17
44	Gebelikte Psikotrop İlaç KullanÄ \pm mÄ \pm : Bir GÃ $\frac{1}{4}$ ncelleme. Journal of Microbiology and Biotechnology, 2011, 21, 161-173.	2.1	7
45	Beyond the glutamate N-methyl D-aspartate receptor in major depressive disorder: the mTOR signaling pathway / Majör depresif bozuklukta glutamat N-metil-D-aspartat reseptörlerinin ötesi: mTOR sinyal yolağı. Journal of Microbiology and Biotechnology, 2011, , 1-6.	2.1	9
46	Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. International Clinical Psychopharmacology, 2010, 25, 165-171.	1.7	36
47	Association Between Symptom Improvement and Change of Body Mass Index, Lipid Profile, and Leptin, Ghrelin, and Cholecystokinin Levels During 6-Week Olanzapine Treatment in Patients With First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2010, 30, 636-638.	1.4	9
48	Farmakoekonomi ve Psikiyatrideki Önemi. Journal of Microbiology and Biotechnology, 2010, 20, 1-4.	2.1	10
49	Modulation of Central Nitric Oxide as a Therapeutic Strategy for Schizophrenia. Journal of Microbiology and Biotechnology, 2010, 20, 115-119.	2.1	7
50	High-Dose Antipsychotic Medication; A Practical Pocket Checklist. Journal of Microbiology and Biotechnology, 2010, 20, 187-188.	2.1	1
51	Psikiyatride Bireye \tilde{A} –zg \tilde{A}^{1} /4 Tedavi: Belki Biraz Eski Veya Biraz Yeni, Ama GeleceÄŸin Tedavisi. Journal of Microbiology and Biotechnology, 2010, 20, 269-273.	2.1	5
52	Evaluation of General Psychopathology, Subjective Sleep Quality, and Health-Related Quality of Life in Patients with Obesity. International Journal of Psychiatry in Medicine, 2009, 39, 297-312.	1.8	34
53	Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 56-60.	1.7	28
54	Body dysmorphic disorder in patients with borderline personality disorder: prevalence, clinical characteristics, and role of childhood trauma. Acta Neuropsychiatrica, 2008, 20, 33-40.	2.1	29

#	Article	IF	CITATIONS
55	A magnetic resonance spectroscopy study of antisocial behaviour disorder, psychopathy and violent crime among military conscripts. Acta Neuropsychiatrica, 2008, 20, 72-77.	2.1	6
56	Nightmare disorder, dream anxiety, and subjective sleep quality in patients with borderline personality disorder. Psychiatry and Clinical Neurosciences, 2008, 62, 48-55.	1.8	107
57	Effects of Diagnostic Comorbidity and Dimensional Symptoms of Attention-Deficit–Hyperactivity Disorder in Men with Antisocial Personality Disorder. Australian and New Zealand Journal of Psychiatry, 2008, 42, 405-413.	2.3	50
58	A Case with Euprolactinemic Galactorrhea Induced by Escitalopram. International Journal of Psychiatry in Medicine, 2007, 37, 275-278.	1.8	22
59	Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1330-1336.	4.8	32
60	Childhood trauma history and dissociative experiences among Turkish men diagnosed with antisocial personality disorder. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 865-873.	3.1	29
61	Identification and posttraumatic stress disorder symptoms in rescue workers in the Marmara, Turkey, earthquake. Journal of Traumatic Stress, 2005, 18, 485-489.	1.8	55
62	Panic disorder due to ingestion of single dose ecstasy. International Journal of Psychiatry in Clinical Practice, 2005, 9, 138-141.	2.4	1
63	Leptospirosis Presenting with Mania and Psychosis: Four Consecutive Cases Seen in a Military Hospital in Turkey. International Journal of Psychiatry in Medicine, 2005, 35, 299-305.	1.8	13
64	Value of regional cerebral blood flow in the evaluation of chronic liver disease and subclinical hepatic encephalopathy. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1162-1167.	2.8	15
65	Urine methylmalonic acid measurements for the assessment of cobalamin deficiency related to neuropsychiatric disorders. Clinical Biochemistry, 2003, 36, 275-282.	1.9	21
66	Body dysmorphic disorder in patients with acne. Comprehensive Psychiatry, 2003, 44, 415-419.	3.1	73
67	Premenstrual exacerbation and suicidal behavior in patients with panic disorder. Comprehensive Psychiatry, 2000, 41, 103-105.	3.1	11
68	Risperidone for the Treatment of Monosymptomatic Hypochondriacal Psychosis. Journal of Clinical Psychiatry, 1999, 60, 554.	2.2	12